Kauppila A, Vapaatalo H, Taskinen P J
Arzneimittelforschung. 1975 Jul;25(7):1082-5.
Thirty-one patients who suffered from various cancers in the pelvic region were treated in a double-blind clinical long-term study either with placebo, N-(2-methyl-3-chlorophenyl)-anthranilic acid (tolfenamic acid, Clotam) or oxyphenbutazone in order to diminish the local reactions after telecobalt therapy. The results were difficult to judge and no clear differences were seen between the groups. The side-effects were slight and unspecific, except gastrointestinal distresses, which occurred with both tolfenamic acid and oxyphenbutazone, but were more severe with the latter. No significant changes were seen in the blood counts, liver or kidney function tests with tolfenamic acid. In the oxyphenbutazone group S-ALAT, S-AFOS and direct bilirubin were slightly elevated. Blood in feces was more frequent in the drug-treated than in the placebo group. In the light of the present and earlier studies tolfenamic acid appears to cause less side-effects than oxyphenbutazone in prolonged treatment.
在一项双盲临床长期研究中，为减轻钴远距离治疗后的局部反应，对31例患有盆腔区域各种癌症的患者使用安慰剂、N-(2-甲基-3-氯苯基)-邻氨基苯甲酸（托芬那酸，氯胺酚）或羟基保泰松进行治疗。结果难以判断，各治疗组之间未观察到明显差异。除胃肠道不适外，副作用轻微且不具特异性，托芬那酸和羟基保泰松均出现胃肠道不适，但后者更严重。使用托芬那酸时，血细胞计数、肝功能或肾功能检查未出现显著变化。在羟基保泰松组中，血清谷丙转氨酶、血清碱性磷酸酶和直接胆红素略有升高。药物治疗组的粪便潜血比安慰剂组更常见。根据目前及早期研究，在长期治疗中，托芬那酸似乎比羟基保泰松引起的副作用更少。
